Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor
OPERATING REVENUE:    
TOTAL OPERATING REVENUE $ 273,544,334 $ 151,297,940
OPERATING EXPENSES:    
Medical Expenses 265,820,802 146,624,505
Premium Deficiency Reserve (1,324,513) 2,000,000
Corporate, General and Administrative Expenses 38,599,412 15,059,076
Sales and Marketing Expenses 864,530 270,241
Amortization of Intangibles 21,161,282  
Depreciation 590,549 332,548
TOTAL OPERATING EXPENSES 325,712,062 164,286,370
OPERATING LOSS (52,167,728) (12,988,430)
OTHER INCOME (EXPENSES):    
Interest Expense, net (2,761,250) (2,124,286)
Mark-to-Market of Stock Warrants (5,861,276) (9,537,996)
TOTAL OTHER INCOME (EXPENSE) (8,622,526) (11,662,282)
LOSS BEFORE INCOME TAXES (60,790,254) (24,650,712)
PROVISION FOR INCOME TAXES 0 0
NET LOSS (60,790,254) (24,650,712)
LESS NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTERESTS (50,212,750)  
NET LOSS ATTRIBUTABLE TO CONTROLLING INTERESTS $ (10,577,504) $ (24,650,712)
NET LOSS PER SHARE (BASIC) $ (0.25)
NET LOSS PER SHARE (DILUTED) $ (0.25)
Capitated Revenue    
OPERATING REVENUE:    
TOTAL OPERATING REVENUE $ 269,684,815 $ 148,964,190
Other Patient Service Revenue    
OPERATING REVENUE:    
TOTAL OPERATING REVENUE $ 3,859,519 $ 2,333,750